Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer

Authors: Peng Chen, Wei-Miao Li, Qiang Lu, Jian Wang, Xiao-Long Yan, Zhi-Pei Zhang, Xiao-Fei Li

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The expression of novel oncogenic kinase (NOK), a member of the protein tyrosine kinase (PTK) family, has been observed in several human malignancies including non-small cell lung cancer (NSCLC). However, the clinic relevance of NOK expression in NSCLC remains unclear.

Methods

In this study, NOK expression in tumor cells was assessed using immunohistochemical methods in 191 patients with resected NSCLC. The association of NOK expression with clinicopathological parameters, including the Ki-67 labeling index (LI), was also evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of NOK expression on survival.

Results

Data showed that NOK was expressed in 75.4% and 14.1% of cancer lesions and corresponding adjacent non-cancerous tissue, respectively. Out of all the clinicopathological factors analyzed, NOK expression was significantly correlated with the grade of tumor differentiation (P = 0.035), pTNM stage (P = 0.020), lymphatic metastasis (P = 0.005) and high Ki-67 LI (P < 0.001). NOK positive NSCLC patients had a significantly shorter survival time (P = 0.004, Log-rank test) and the prognostic significance of NOK expression was apparent in squamous cell carcinoma patients (P = 0.022). Multivariate analysis indicated that NOK expression may be an independent prognostic factor in NSCLC (hazard ratio [HR], 1.731; P = 0.043).

Conclusions

Our results indicate that NOK expression is of clinical significance and can serve as a prognostic biomarker in NSCLC.
Appendix
Available only for authorised users
Literature
1.
Reungwetwattana T, Weroha SJ, Molina JR: Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer. 2012, 13: 252-266. 10.1016/j.cllc.2011.09.004.CrossRefPubMed
2.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed
3.
Pfannschmidt J, Muley T, Bulzebruck H, Hoffmann H, Dienemann H: Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer. 2007, 55: 371-377. 10.1016/j.lungcan.2006.10.017.CrossRefPubMed
4.
Ye X, Ji C, Huang Q, Cheng C, Tang R, Xu J, Zeng L, Dai J, Wu Q, Gu S, Xie Y, Mao Y: Isolation and characterization of a human putative receptor protein kinase cDNA STYK1. Mol Biol Rep. 2003, 30: 91-96. 10.1023/A:1023934017174.CrossRefPubMed
5.
Liu L, Yu XZ, Li TS, Song LX, Chen PL, Suo TL, Li YH, Wang SD, Chen Y, Ren YM, Zhang SP, Chang ZJ, Fu XY: A novel protein tyrosine kinase NOK that shares homology with platelet- derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res. 2004, 64: 3491-3499. 10.1158/0008-5472.CAN-03-2106.CrossRefPubMed
6.
Chen Y, Li YH, Chen XP, Gong LM, Zhang SP, Chang ZJ, Zhang XF, Fu XY, Liu L: Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice. Cancer Res. 2005, 65: 10838-10846. 10.1158/0008-5472.CAN-05-1091.CrossRefPubMed
7.
Moriai R, Kobayashi D, Amachika T, Tsuji N, Watanabe N: Diagnostic relevance of overexpressed NOK mRNA in breast cancer. Anticancer Res. 2006, 26: 4969-4973.PubMed
8.
Amachika T, Kobayashi D, Moriai R, Tsuji N, Watanabe N: Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer. 2007, 56: 337-340. 10.1016/j.lungcan.2007.01.002.CrossRefPubMed
9.
Jackson KA, Oprea G, Handy J, Kimbro KS: Aberrant STYK1 expression in ovarian cancer tissues and cell lines. J Ovarian Res. 2009, 2: 15-10.1186/1757-2215-2-15.CrossRefPubMedPubMedCentral
10.
Kondoh T, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N: Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia. Exp Hematol. 2009, 37: 824-830. 10.1016/j.exphem.2009.04.010.CrossRefPubMed
11.
Zhang Z, Jiang T, Deng Y, Wang P, Wang J, Gu Z, Han Y, Wang Y, Zhao J, Chang Z, Li X: Expression and its Clinical Significance of NOK, EGFR in NSCLC. Zhongguo Fei Ai Za Zhi. 2009, 12: 983-988.PubMed
12.
Li J, Wu F, Sheng F, Li YJ, Jin D, Ding X, Zhang S: NOK/STYK1 interacts with GSK-3beta and mediates Ser9 phosphorylation through activated Akt. FEBS Lett. 2012, 586: 3787-3792. 10.1016/j.febslet.2012.09.011.CrossRefPubMed
13.
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007, 2: 706-714. 10.1097/JTO.0b013e31812f3c1a.CrossRefPubMed
14.
Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature. 2001, 411: 355-365. 10.1038/35077225.CrossRefPubMed
15.
Hubbard SR, Miller WT: Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol. 2007, 19: 117-123. 10.1016/j.ceb.2007.02.010.CrossRefPubMedPubMedCentral
16.
Muller-Tidow C, Diederichs S, Bulk E, Pohle T, Steffen B, Schwable J, Plewka S, Thomas M, Metzger R, Schneider PM, Brandts CH, Berdel WE, Serve H: Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res. 2005, 65: 1778-1782. 10.1158/0008-5472.CAN-04-3388.CrossRefPubMed
17.
Madhusudan S, Ganesan TS: Tyrosine kinase inhibitors in cancer therapy. Clinical Biochemistry. 2004, 37: 618-635. 10.1016/j.clinbiochem.2004.05.006.CrossRefPubMed
18.
Wu M, Zhao J, Song SW, Zhuo M, Wang X, Bai H, Wang S, Yang L, An T, Zhang Y, Duan J, Wang Y, Guo Q, Liu X, Liu N, Wang J: EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2010, 67: 343-347. 10.1016/j.lungcan.2009.04.011.CrossRefPubMed
19.
Zinner RG, Kim J, Herbst RS: Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer. 2002, 37: 17-27. 10.1016/S0169-5002(02)00035-1.CrossRefPubMed
20.
Lee MY, Chou CY, Tang MJ, Shen MR: Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res. 2008, 14: 4743-4750. 10.1158/1078-0432.CCR-08-0234.CrossRefPubMed
21.
Luo J: Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 2009, 273: 194-200. 10.1016/j.canlet.2008.05.045.CrossRefPubMed
22.
Doble BW, Woodgett JR: Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs. 2007, 185: 73-84. 10.1159/000101306.CrossRefPubMed
23.
Li YH, Wang YY, Zhong S, Rong ZL, Ren YM, Li ZY, Zhang SP, Chang ZJ, Liu L: Transmembrane helix of novel oncogene with kinase-domain (NOK) influences its oligomerization and limits the activation of RAS/MAPK signaling. Mol Cells. 2009, 27: 39-45. 10.1007/s10059-009-0003-5.CrossRefPubMed
24.
Kim EK, Choi E-J: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta (BBA) - Molecular Basis of Disease. 2010, 1802: 396-405. 10.1016/j.bbadis.2009.12.009.CrossRef
25.
Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007, 7: 295-308. 10.1038/nrc2109.CrossRefPubMed
26.
Chen P, Zhang ZP, Jin HT, Liu T, Li XF: Impact of STYK1/NOK gene transfection on the migration and invasion of lung adenocarcinoma cell line. Chin J Cancer Prev Treat. 2011, 18: 564-567.
27.
Liu T, Zhang ZP, Li XF: Effect of NOK over expression on proliferation of lung adenocarcinoma cell SPC-A-1. Modern Oncology. 2012, 20: 1327-1330.
28.
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010, 363: 1693-1703. 10.1056/NEJMoa1006448.CrossRefPubMedPubMedCentral
29.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009, 361: 947-957. 10.1056/NEJMoa0810699.CrossRefPubMed
30.
Ding X, Jiang QB, Li R, Chen S, Zhang S: NOK/STYK1 has a strong tendency towards forming aggregates and colocalises with epidermal growth factor receptor in endosomes. Biochem Biophys Res Commun. 2012, 421: 468-473. 10.1016/j.bbrc.2012.04.016.CrossRefPubMed
Metadata
Title
Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer
Authors
Peng Chen
Wei-Miao Li
Qiang Lu
Jian Wang
Xiao-Long Yan
Zhi-Pei Zhang
Xiao-Fei Li
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-402

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

The impact of a cancer diagnosis on weight change: findings from prospective, population-based cohorts in the UK and the US

Research article

Fast-track surgery versus traditional perioperative care in laparoscopic colorectal cancer surgery: a meta-analysis

Research article

The clinical features and treatment modality of esophageal neuroendocrine tumors: a multicenter study in Korea

Research article

An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents

Research article

Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1

Research article

Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits